---
title: A First-in-Class JAK/ROCK Inhibitor, Rovadicitinib, for Glucocorticoid-Refractory
  or -Dependent Chronic GVHD
date: '2025-02-26'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/40009501/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20250227170931&v=2.18.0.post9+e462414
source: Blood
description: Rovadicitinib (TQ05105) is a novel, oral dual JAK1/2 and ROCK1/2 inhibitor
  targeting inflammatory and fibrotic components of chronic graft-versus-host disease
  (cGVHD). We aimed to evaluate the safety and efficacy of rovadicitinib for glucocorticoid-refractory
  or -dependent cGVHD. This phase 1b/2a, multicenter, open-label study (NCT04944043)
  enrolled patients with moderate or severe glucocorticoid-refractory or -dependent
  cGVHD. The study followed a 3+3 design with two escalating ...
disable_comments: true
---
Rovadicitinib (TQ05105) is a novel, oral dual JAK1/2 and ROCK1/2 inhibitor targeting inflammatory and fibrotic components of chronic graft-versus-host disease (cGVHD). We aimed to evaluate the safety and efficacy of rovadicitinib for glucocorticoid-refractory or -dependent cGVHD. This phase 1b/2a, multicenter, open-label study (NCT04944043) enrolled patients with moderate or severe glucocorticoid-refractory or -dependent cGVHD. The study followed a 3+3 design with two escalating ...